MissionNMD Pharma is dedicated to developing novel treatments to improve muscle function and quality of life of patients with neuromuscular disease.VisionA future in which patients with neuromuscular disease live better and more independent lives.We have a unique translational muscle electrophysiology platform leveraging in-depth know-how of muscle physiology and muscular disorders for discovering and developing first-in-class therapeutics in neuromuscular diseases with a significant unmet medical need.NMD Pharma is the leading company utilizing ClC-1 Cl- ion channel inhibitors for neuromuscular diseases and currently has one clinical-stage product candidate for the treatment of myasthenia gravis.We have more than 25 employees with expertise in all areas of drug development. We are headquartered in Aarhus, Denmark, and collaborate with internationally renowned companies and key opinion leaders in the field of neuromuscular diseases.For more information, please visit the company website.

Novo Holdings

Inkef

Roche Venture Fund

Lundbeckfonden Emerge

Jeito Capital

CAPNOVA

NMD Pharma A/S

Epirium Bio is a biotechnology company focused on developing therapeutics for neuromuscular diseases.

Epirium Bio

PepGen is a biotechnology company specializing in the development of therapeutics for neuromuscular diseases.

PepGen

Sarepta Therapeutics is a leading biopharmaceutical company focused on developing RNA-targeted therapeutics for rare neuromuscular diseases.

Sarepta Therapeutics

NMD Pharma is a clinical-stage biotech company focused on developing first-in-class, small molecule ClC-1 inhibitors targeting muscle function within neuromuscular disorders. Their initial focus is on diseases such as myasthenia gravis, spinal muscular atrophy, Charcot-Marie Tooth’s disease, and sarcopenia.

news_impact_assignment_basic

key_people

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

merger_acquisitions

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general	Mar 1, 2024 11:01 PM	ccd7bb28
public peers	general
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general	Mar 1, 2024 11:01 PM	e4efa716
company summary	general
signals	general
crunchbase trigger	general
crunchbase profile	general
li profile	general	Mar 1, 2024 11:01 PM	52a2b689
translate crunchbase fundingrounds	general
peers	general
news basic	general	Mar 1, 2024 11:01 PM	b8950c9e
bundesanzeiger	filings
merger acquisitions	company_analysis
financials download nd	financials
private financials	financials

COM:NMDPHARMA

NMD Pharma A/S